Angiosarcoma is a highly malignancy of endothelial tumor and represents 1-2% of all soft
tissue sarcomas in humans. The aetiology of angiosarcoma is not clear but there are definite …

Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that have a poor
prognosis. They can arise anywhere in the body, most commonly presenting as cutaneous …

Soft-tissue sarcomas have traditionally been managed by wide excisional surgery and
radiotherapy, with chemotherapy reserved for advanced disease. However, advances in …

Background To determine efficacy and safety of bevacizumab, a recombinant humanized
antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or …

Purpose Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an
oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and …

Purpose The objective of this phase II trial was to assess the efficacy and toxicity of weekly
paclitaxel for patients with metastatic or unresectable angiosarcoma. Patients and Methods …

Purpose Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality.
Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no …

Purpose Since activity of sorafenib was observed in sarcoma patients in a phase I study, we
performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or …

PURPOSE Angiosarcoma is a rare vascular malignancy, and there are few published data
to guide chemotherapy treatment decisions. We present a retrospective analysis of …

BACKGROUND Angiosarcoma is a malignant tumor of vascular endothelial cells that arises
in the head and neck. It is a rare, difficult to treat, and lethal tumor. METHODS Clinical data …